New Generic Approvals
Generics of Viibryd, Tranxane and Timoptic have recently been approved and launched.
Accord Healthcare releases generic of Viibryd
Accord Healthcare has launched vilazodone tablets. The drug is therapeutically equivalent to Allergan’s Viibryd and is approved to treat major depressive disorder (MDD) in adults. Accord’s product, offered in 10 mg, 20 mg, and 40 mg tablets, is currently available to ship.
Depression is a leading cause of disability worldwide. It is a serious mood disorder that affects how people think, feel, and handle daily activities like sleeping and eating. Globally, roughly 5% of adults suffer from MDD.
FDA approves Ani’s generic of Tranxene.
The FDA has approved the abbreviated new drug application for Ani Pharmaceuticals’ clorazepate dipotassium tablets, the generic version of Tranxene. It is a benzodiazepine is used to treat patients with anxiety, alcohol withdrawal and as an add-on for seizures. Executives from Ani said the launch of its generic is imminent.
Amring receives approval and launches generic of Timoptic
Amring Pharmaceuticals has received FDA approval for generic timolol maleate ophthalmic solution, which is the generic equivalent of Merck’s Timoptic in Ocudose. Timolol maleate ophthalmic solution is supplied in a 60 pack of 0.3mL single-dose vials. It is indicated for the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma.
In this episode of the "Meet the Board" podcast series, Briana Contreras, Managed Healthcare Executive editor, speaks with Ateev Mehrotra, a member of the MHE editorial advisory board and a professor of healthcare policy and medicine at Harvard Medical School. Mehtrotra is also a hospitalist at the Beth Israel Deaconess Medical Center in Boston. In the discussion, Contreras gets to know Mehrotra more on a personal level and picks his brain on some of his research interests including telehealth, alternative payment models and price transparency.
Listen
